Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N H Russell

Showing results (121-130 of 156) with videos related to

Pageof 16
Sort By:
Leukemia Research Reports|December 28, 2013
Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalitiesM Dennis, D Culligan, D Karamitros, et al.
British Journal of Haematology|May 3, 2000
Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicityG M Cull, A P Haynes, J L Byrne, et al.
Leukemia|June 8, 2018
A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 TrialA K Burnett, R K Hills, O J Nielsen, et al.
Leukemia|October 27, 2006
DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412C H Seedhouse, H M Hunter, B Lloyd-Lewis, et al.
Bone Marrow Transplantation|September 11, 2001
Accelerated telomere shortening following allogeneic transplantation is independent of the cell source and occurs within the first year post transplantJ D Robertson, N G Testa, N H Russell, et al.
Bone Marrow Transplantation|October 26, 2005
Management of chronic myeloid leukaemia in relapse following donor lymphocyte infusion induced remission: a retrospective study of the Clinical Trials Committee of the British Society of Blood & Marrow Transplantation (BSBMT)M Cummins, K Cwynarski, S Marktel, et al.
Bone Marrow Transplantation|January 1, 1997
Allogeneic peripheral blood stem cell transplantation for haematological malignancies--an analysis of kinetics of engraftment and GVHD riskG Miflin, N H Russell, R M Hutchinson, et al.
Cytotherapy|June 5, 2002
An analysis of the effect of chronic GvHD on relapse and survival following allogeneic PBSC transplantationG Miflin, N H Russell, I Franklin, et al.
Plos One|January 13, 2022
Comparative analysis of DNA extraction and PCR product purification methods for cervicovaginal microbiome analysis using cpn60 microbial profilingElinor Shvartsman, Meika E I Richmond, John J Schellenberg, et al.
Leukemia|September 12, 2012
The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparisonA K Burnett, R K Hills, A E Hunter, et al.
Pageof 16

Showing results (121-130 of 156) with videos related to

Sort By:
Pageof 16
Leukemia Research Reports|December 28, 2013
Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalitiesM Dennis, D Culligan, D Karamitros, et al.
British Journal of Haematology|May 3, 2000
Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicityG M Cull, A P Haynes, J L Byrne, et al.
Leukemia|June 8, 2018
A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 TrialA K Burnett, R K Hills, O J Nielsen, et al.
Leukemia|October 27, 2006
DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412C H Seedhouse, H M Hunter, B Lloyd-Lewis, et al.
Bone Marrow Transplantation|September 11, 2001
Accelerated telomere shortening following allogeneic transplantation is independent of the cell source and occurs within the first year post transplantJ D Robertson, N G Testa, N H Russell, et al.
Bone Marrow Transplantation|October 26, 2005
Management of chronic myeloid leukaemia in relapse following donor lymphocyte infusion induced remission: a retrospective study of the Clinical Trials Committee of the British Society of Blood & Marrow Transplantation (BSBMT)M Cummins, K Cwynarski, S Marktel, et al.
Bone Marrow Transplantation|January 1, 1997
Allogeneic peripheral blood stem cell transplantation for haematological malignancies--an analysis of kinetics of engraftment and GVHD riskG Miflin, N H Russell, R M Hutchinson, et al.
Cytotherapy|June 5, 2002
An analysis of the effect of chronic GvHD on relapse and survival following allogeneic PBSC transplantationG Miflin, N H Russell, I Franklin, et al.
Plos One|January 13, 2022
Comparative analysis of DNA extraction and PCR product purification methods for cervicovaginal microbiome analysis using cpn60 microbial profilingElinor Shvartsman, Meika E I Richmond, John J Schellenberg, et al.
Leukemia|September 12, 2012
The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparisonA K Burnett, R K Hills, A E Hunter, et al.
Pageof 16